达罗他胺 API

作用机制

Darolutamide belongs to a class of drugs called androgen receptor antagonists. Here's how it disrupts prostate cancer cell growth:

Androgen and Androgen Receptors: Prostate cancer cells rely on male hormones called androgens, particularly testosterone, to grow and survive. These androgens bind to androgen receptors located inside the cancer cells.

Blocking Androgen Binding: Darolutamide acts by competitively binding to these androgen receptors. By occupying the receptor sites, it prevents testosterone and other androgens from attaching and triggering growth signals.

Downstream Effects: This blockade disrupts the normal function of androgen receptors, ultimately leading to a decrease in prostate cancer cell proliferation and potentially a reduction in tumor size.

适应症

Darolutamide is currently approved for two main indications in adult males:

Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC): This refers to prostate cancer that has not yet spread to other parts of the body (non-metastatic) but is no longer responding to treatments that lower testosterone levels (castration-resistant). Darolutamide is typically used in combination with surgical or medical castration.

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): This is a more advanced stage of prostate cancer where the cancer has already spread (metastatic) but still responds to lowering testosterone levels (hormone-sensitive). Here, Darolutamide is used in combination with docetaxel (chemotherapy medication).

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴，是全球领先的活性药物成分（API）供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API（如类固醇，多肽，复杂长链分子和高效API（HPAPI /肿瘤药物））方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准，从而为这一专业知识提供补充。 Dr. Reddy's博士 达罗他胺 API是研发，知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量，安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化，从而避免短缺并满足需求的突然激增。